Azathioprine or Mycophenolate mofetil
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid
Conditions
Bullous Pemphigoid
Trial Timeline
Oct 1, 1997 → Oct 1, 2000
NCT ID
NCT00431119About Azathioprine or Mycophenolate mofetil
Azathioprine or Mycophenolate mofetil is a phase 2 stage product being developed by Roche for Bullous Pemphigoid. The current trial status is completed. This product is registered under clinical trial identifier NCT00431119. Target conditions include Bullous Pemphigoid.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00431119 | Phase 2 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| dupilumab + Matching Placebo + Oral corticosteroids (OCS) | Sanofi | Phase 2/3 | 64 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| BIV009 | Sanofi | Phase 1 | 32 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 3 | 74 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 2/3 | 62 |